erythromycin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 1048 114-07-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • erythromycin gluceptate
  • erythromycin lactobionate
  • erythromycin stearate
  • erythromycin
  • Erythromycin A
  • erythrocin
A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.
  • Molecular weight: 733.94
  • Formula: C37H67NO13
  • CLOGP: 1.61
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 5
  • TPSA: 193.91
  • ALOGS: -3.20
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O
2 g O
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 90.88 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 35 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.95 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 24, 1964 FDA ARBOR PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 4904.84 12.44 2217 17579 263025 53066245
International normalised ratio fluctuation 195.02 12.44 60 19736 2283 53326987
Bloody discharge 121.70 12.44 36 19760 1195 53328075
Seronegative arthritis 88.49 12.44 32 19764 2015 53327255
Lyme disease 83.62 12.44 33 19763 2644 53326626
Necrosis ischaemic 63.11 12.44 20 19776 839 53328431
Exposure during pregnancy 62.48 12.44 141 19655 124719 53204551
Anaphylactic reaction 60.02 12.44 90 19706 58236 53271034
Dislocation of vertebra 53.19 12.44 24 19772 2682 53326588
Drug interaction 50.24 12.44 187 19609 219142 53110128
Beta haemolytic streptococcal infection 49.68 12.44 21 19775 2006 53327264
Pneumonia streptococcal 49.07 12.44 20 19776 1743 53327527
Amniotic cavity infection 44.43 12.44 17 19779 1253 53328017
Faecal volume decreased 43.69 12.44 11 19785 196 53329074
Wheezing 41.09 12.44 81 19715 65194 53264076
Drug intolerance 39.60 12.44 166 19630 205327 53123943
Pneumococcal infection 39.26 12.44 12 19784 446 53328824
Ototoxicity 38.09 12.44 15 19781 1195 53328075
Vomiting 37.38 12.44 313 19483 496826 52832444
Rash 36.83 12.44 287 19509 445904 52883366
Death 35.98 12.44 48 19748 357184 52972086
Purpura senile 35.65 12.44 12 19784 610 53328660
Umbilical erythema 35.11 12.44 8 19788 91 53329179
Completed suicide 34.70 12.44 5 19791 138196 53191074
Vertigo positional 34.29 12.44 18 19778 2798 53326472
Caesarean section 34.22 12.44 37 19759 17283 53311987
Death neonatal 31.99 12.44 9 19787 249 53329021
Tarsal tunnel syndrome 31.35 12.44 11 19785 634 53328636
Stevens-Johnson syndrome 31.28 12.44 42 19754 24540 53304730
Drug tolerance decreased 30.91 12.44 24 19772 7334 53321936
Abortion spontaneous 30.72 12.44 59 19737 46576 53282694
Spondylitis 27.75 12.44 16 19780 2987 53326283
Infection 27.06 12.44 131 19665 172074 53157196
Premature baby 27.00 12.44 35 19761 19766 53309504
Therapeutic product effect incomplete 26.86 12.44 85 19711 91699 53237571
Wound infection 26.79 12.44 28 19768 12579 53316691
Mass excision 26.69 12.44 8 19788 278 53328992
Pain 26.16 12.44 121 19675 588277 52740993
Serum sickness-like reaction 25.86 12.44 9 19787 506 53328764
Resorption bone increased 25.25 12.44 11 19785 1131 53328139
Bronchial obstruction 24.83 12.44 12 19784 1566 53327704
Breast cancer stage III 24.26 12.44 14 19782 2618 53326652
Oligohydramnios 23.76 12.44 19 19777 6057 53323213
Fall 23.05 12.44 63 19733 358377 52970893
Vestibular disorder 23.02 12.44 11 19785 1400 53327870
Premature rupture of membranes 22.70 12.44 17 19779 4923 53324347
Adjustment disorder with depressed mood 21.87 12.44 13 19783 2567 53326703
Spinal fusion surgery 21.18 12.44 15 19781 3986 53325284
Lip swelling 21.18 12.44 37 19759 27164 53302106
Maternal drugs affecting foetus 20.96 12.44 17 19779 5529 53323741
Cardiac arrest neonatal 19.41 12.44 5 19791 98 53329172
Pharyngeal oedema 18.64 12.44 25 19771 14588 53314682
Corneal neovascularisation 18.53 12.44 5 19791 118 53329152
Corneal perforation 18.41 12.44 7 19789 507 53328763
Abdominal pain upper 18.37 12.44 115 19681 166176 53163094
Thrombophlebitis superficial 18.12 12.44 15 19781 5020 53324250
Stenotrophomonas infection 18.07 12.44 10 19786 1726 53327544
Diffuse panbronchiolitis 17.76 12.44 3 19793 5 53329265
Mucous stools 17.55 12.44 12 19784 3014 53326256
Acute generalised exanthematous pustulosis 16.96 12.44 20 19776 10261 53319009
Infantile haemangioma 16.66 12.44 4 19792 58 53329212
Urticaria 15.65 12.44 95 19701 135790 53193480
Infusion related reaction 15.62 12.44 21 19775 155936 53173334
Starvation ketoacidosis 15.59 12.44 4 19792 77 53329193
Nasopharyngitis 15.40 12.44 30 19766 192265 53137005
Hypersensitivity 15.40 12.44 132 19664 210533 53118737
Ergot poisoning 15.40 12.44 5 19791 227 53329043
Blepharitis 15.33 12.44 10 19786 2324 53326946
Alopecia 15.23 12.44 41 19755 234542 53094728
Drug ineffective 14.16 12.44 216 19580 817029 52512241
Anal candidiasis 14.12 12.44 3 19793 24 53329246
Febrile neutropenia 14.05 12.44 11 19785 104925 53224345
Anaemia 14.04 12.44 54 19742 276664 53052606
Keratitis 14.02 12.44 10 19786 2687 53326583
Neutropenia 13.48 12.44 24 19772 159161 53170109
Dysphoria 13.42 12.44 13 19783 5336 53323934
Haemorrhagic diathesis 13.39 12.44 12 19784 4466 53324804
Wrong technique in product usage process 13.27 12.44 3 19793 60029 53269241
Haemoglobin decreased 13.23 12.44 19 19777 137288 53191982
Product packaging issue 13.18 12.44 7 19789 1114 53328156
Nodule 12.66 12.44 23 19773 17406 53311864
Stillbirth 12.52 12.44 14 19782 6783 53322487
Ulcerative keratitis 12.48 12.44 9 19787 2460 53326810

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 472.37 14.28 273 8310 73127 32431816
Hyphaema 75.50 14.28 19 8564 483 32504460
Product packaging issue 63.18 14.28 17 8566 565 32504378
Toxic epidermal necrolysis 62.09 14.28 48 8535 20545 32484398
Drug interaction 60.66 14.28 159 8424 218026 32286917
Dystonia 43.95 14.28 30 8553 10593 32494350
Stupor 38.98 14.28 18 8565 2991 32501952
Rhabdomyolysis 35.94 14.28 64 8519 67201 32437742
Premature baby 34.95 14.28 33 8550 18485 32486458
Obstruction gastric 33.83 14.28 12 8571 1009 32503934
Coagulation time prolonged 33.77 14.28 13 8570 1375 32503568
Oligohydramnios 32.31 14.28 9 8574 341 32504602
Intraocular pressure increased 30.83 14.28 19 8564 5639 32499304
Acute generalised exanthematous pustulosis 30.54 14.28 20 8563 6593 32498350
Eye pain 30.20 14.28 26 8557 12922 32492021
Brain oedema 30.18 14.28 26 8557 12934 32492009
Foetal death 29.90 14.28 8 8575 260 32504683
Deafness bilateral 29.26 14.28 11 8572 1091 32503852
Pyloric stenosis 28.73 14.28 10 8573 795 32504148
SAPHO syndrome 28.47 14.28 6 8577 67 32504876
Caesarean section 28.35 14.28 13 8570 2126 32502817
Product dispensing error 26.03 14.28 18 8565 6487 32498456
Foetal arrhythmia 25.80 14.28 6 8577 108 32504835
Maternal drugs affecting foetus 24.94 14.28 15 8568 4262 32500681
Learning disorder 24.39 14.28 9 8574 847 32504096
Onychophagia 23.09 14.28 5 8578 64 32504879
Oculogyric crisis 22.97 14.28 10 8573 1447 32503496
Ototoxicity 22.00 14.28 10 8573 1602 32503341
Respiratory acidosis 21.94 14.28 14 8569 4414 32500529
Tricuspid valve disease 21.83 14.28 6 8577 216 32504727
Hepatic necrosis 20.78 14.28 13 8570 3962 32500981
Myasthenia gravis crisis 20.40 14.28 7 8576 533 32504410
Pneumonia mycoplasmal 19.91 14.28 7 8576 573 32504370
Vasculitic rash 19.78 14.28 8 8575 964 32503979
Torsade de pointes 19.58 14.28 16 8567 7399 32497544
Febrile neutropenia 19.35 14.28 4 8579 119562 32385381
Accidental exposure to product 19.32 14.28 19 8564 11183 32493760
Ischaemic hepatitis 18.34 14.28 9 8574 1710 32503233
Potentiating drug interaction 18.05 14.28 13 8570 4995 32499948
Pathogen resistance 18.04 14.28 17 8566 9493 32495450
Cardio-respiratory arrest neonatal 17.56 14.28 3 8580 9 32504934
Myoglobinuria 17.48 14.28 7 8576 822 32504121
Impaired gastric emptying 17.39 14.28 11 8572 3415 32501528
Altered state of consciousness 17.32 14.28 25 8558 21972 32482971
Folliculitis 17.24 14.28 12 8571 4368 32500575
Swelling face 16.89 14.28 25 8558 22480 32482463
Hepatic failure 16.59 14.28 32 8551 35648 32469295
Exposure during pregnancy 16.56 14.28 16 8567 9213 32495730
Neonatal disorder 16.48 14.28 7 8576 954 32503989
Sepsis neonatal 16.42 14.28 5 8578 260 32504683
Premature rupture of membranes 16.19 14.28 3 8580 16 32504927
Brain herniation 16.17 14.28 11 8572 3860 32501083
Pupillary disorder 15.92 14.28 5 8578 288 32504655
Stevens-Johnson syndrome 15.82 14.28 22 8561 18687 32486256
Foetal exposure during pregnancy 15.60 14.28 34 8549 41267 32463676
Visual acuity reduced 14.91 14.28 20 8563 16425 32488518
Pneumonia escherichia 14.66 14.28 5 8578 374 32504569
Multiple organ dysfunction syndrome 14.53 14.28 46 8537 69808 32435135

Pharmacologic Action:

SourceCodeDescription
ATC D10AF02 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Antiinfectives for treatment of acne
ATC D10AF52 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Antiinfectives for treatment of acne
ATC J01FA01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Macrolides
ATC S01AA17 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
FDA CS M0028311 Macrolides
FDA PE N0000009982 Decreased Sebaceous Gland Activity
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
FDA EPC N0000175877 Macrolide
FDA EPC N0000175935 Macrolide Antimicrobial

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Listeriosis indication 4241002 DOID:11573
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Pertussis indication 27836007
Acute gonococcal urethritis indication 29864006
Neonatal conjunctivitis indication 34298002 DOID:9699
Gonorrhea of rectum indication 42746002
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Bacterial pneumonia indication 53084003 DOID:874
Acute gonococcal endometritis indication 65295003 DOID:7527
Acute bacterial sinusitis indication 75498004
Syphilis indication 76272004
Pneumococcal pharyngitis indication 76651006
Nongonococcal urethritis indication 84619001
Acne vulgaris indication 88616000
Urethritis due to Chlamydia trachomatis indication 179101003
Chlamydial conjunctivitis indication 231861005 DOID:13800
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Neonatal pneumonia indication 233619008
Erythrasma indication 238418005 DOID:4131
Streptococcus pyogenes infection indication 302809008
Infective otitis media indication 312218008
Diphtheria indication 397428000
Infection due to Staphylococcus aureus indication 406602003
Recurrent Persistent Urethritis indication
Superficial Ocular Infection indication
Preoperative Bowel Preparation indication
Prevention of Bacterial Endocarditis indication
Chlamydia Cervicitis indication
Rectal Chlamydia Trachomatis Infection indication
Prevention of Neonatal Ophthalmia indication
Pneumococcal Acute Otitis Media indication
Legionnaires' Disease indication
Rheumatic Fever Prevention indication
Haemophilus Influenzae Acute Otitis Media indication
Trachoma off-label use 2576002 DOID:11265
Inhalational anthrax off-label use 11389007
Actinomycotic infection off-label use 11817007 DOID:8478
Enteric campylobacteriosis off-label use 18081009
Lyme disease off-label use 23502006 DOID:11729
Granuloma inguinale off-label use 28867007 DOID:9113
Sinusitis off-label use 36971009
Erysipelas off-label use 44653001 DOID:11330
Blepharoconjunctivitis off-label use 68659002 DOID:2456
Cutaneous anthrax off-label use 84980006 DOID:7426
Ecthyma off-label use 85791004
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Bacterial conjunctivitis off-label use 128350005 DOID:9700
Bacterial infection of skin off-label use 128936008
Lymphogranuloma venereum off-label use 186946009 DOID:13819
Gastroesophageal reflux disease off-label use 235595009 DOID:8534
Gastroparesis off-label use 235675006
Chancroid off-label use 266143009 DOID:13778
Meibomianitis off-label use 309779001
Infective blepharitis off-label use 312219000
Bacterial keratitis off-label use 314557000
Erysipeloid off-label use 400105005
Anthrax off-label use 409498004 DOID:7427
Relapsing fever off-label use 420079008 DOID:13034
Gastroscopy Adjunct off-label use
Listeria Monocytogenes Septicemia off-label use
Ureaplasma Pneumonia off-label use
Torsades de pointes contraindication 31722008
Third trimester pregnancy contraindication 41587001
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Cholestatic hepatitis contraindication 95556007
Anemia due to enzyme deficiency contraindication 111577008
Prolonged QT interval contraindication 111975006
Hearing disorder contraindication 128540005
Liver function tests abnormal contraindication 166603001
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000
Erythroderma contraindication 399992009
Porphyria contraindication 418470004
Congenital long QT syndrome contraindication 442917000
Inflammatory dermatosis contraindication 703938007

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
250MG ERYTHROMYCIN TORRENT A211975 July 26, 2021 RX TABLET, DELAYED RELEASE ORAL April 2, 2022 COMPETITIVE GENERIC THERAPY
500MG ERYTHROMYCIN TORRENT A211975 July 26, 2021 RX TABLET, DELAYED RELEASE ORAL April 2, 2022 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 7.41 CHEMBL
Aldehyde oxidase Enzyme IC50 4.82 WOMBAT-PK
Bile salt export pump Transporter IC50 5.39 CHEMBL
Motilin receptor GPCR Ki 4.43 CHEMBL
Cytochrome P450 1B1 Enzyme IC50 4.40 CHEMBL

External reference:

IDSource
4017594 VUID
N0000145975 NUI
D00140 KEGG_DRUG
23067-13-2 SECONDARY_CAS_RN
4017591 VANDF
4017594 VANDF
4017595 VANDF
4017596 VANDF
C0014806 UMLSCUI
CHEBI:42355 CHEBI
ERY PDB_CHEM_ID
CHEMBL2110577 ChEMBL_ID
CHEMBL532 ChEMBL_ID
CHEMBL1200506 ChEMBL_ID
CHEMBL3545060 ChEMBL_ID
CHEMBL1200510 ChEMBL_ID
D004917 MESH_DESCRIPTOR_UI
DB00199 DRUGBANK_ID
C010948 MESH_SUPPLEMENTAL_RECORD_UI
C011462 MESH_SUPPLEMENTAL_RECORD_UI
1456 IUPHAR_LIGAND_ID
39 INN_ID
63937KV33D UNII
12560 PUBCHEM_CID
24346 RXNORM
33316 MMSL
3627 MMSL
4675 MMSL
4678 MMSL
4679 MMSL
4680 MMSL
4769 MMSL
4799 MMSL
72164 MMSL
d00046 MMSL
002755 NDDF
002758 NDDF
002759 NDDF
002760 NDDF
30427009 SNOMEDCT_US
372694001 SNOMEDCT_US
39152007 SNOMEDCT_US
698006 SNOMEDCT_US
83981000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0093-5571 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0093-5572 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
ERYGEL HUMAN PRESCRIPTION DRUG LABEL 1 0378-8075 GEL 20 mg TOPICAL NDA 18 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0378-8212 GEL 20 mg TOPICAL NDA authorized generic 18 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0404-7191 OINTMENT 5 mg OPHTHALMIC ANDA 18 sections
Erythrocin Lactobionate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6476 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 13 sections
Erythrocin Lactobionate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6482 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 13 sections
erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0574-4024 OINTMENT 5 mg OPHTHALMIC ANDA 18 sections
Erythrocin Stearate HUMAN PRESCRIPTION DRUG LABEL 1 10544-594 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Erythrocin Stearate HUMAN PRESCRIPTION DRUG LABEL 1 10544-595 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 13668-586 TABLET, DELAYED RELEASE 250 mg ORAL ANDA 25 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 13668-588 TABLET, DELAYED RELEASE 500 mg ORAL ANDA 25 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 13668-606 TABLET, COATED 250 mg ORAL ANDA 14 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 13668-607 TABLET, COATED 500 mg ORAL ANDA 14 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 13985-605 OINTMENT 5 mg OPHTHALMIC ANDA 18 sections
Erythromycin Lactobionate HUMAN PRESCRIPTION DRUG LABEL 1 14789-116 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 24 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-088 CAPSULE, DELAYED RELEASE 250 mg ORAL ANDA 22 sections
ERY-TAB HUMAN PRESCRIPTION DRUG LABEL 1 16590-089 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 27 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-090 OINTMENT 5 mg OPHTHALMIC ANDA 9 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-091 TABLET, FILM COATED 250 mg ORAL ANDA 17 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 17478-070 OINTMENT 5 mg OPHTHALMIC ANDA 19 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 21695-173 OINTMENT 5 mg OPHTHALMIC ANDA 15 sections
ERYTHROMYCIN Base Filmtab HUMAN PRESCRIPTION DRUG LABEL 1 21695-387 TABLET, FILM COATED 250 mg ORAL ANDA 24 sections
ERYTHROMYCIN Base Filmtab HUMAN PRESCRIPTION DRUG LABEL 1 21695-389 TABLET, FILM COATED 500 mg ORAL ANDA 24 sections
ERY-TAB HUMAN PRESCRIPTION DRUG LABEL 1 21695-457 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 23 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 24208-910 OINTMENT 5 mg OPHTHALMIC ANDA 8 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 24338-102 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 24338-104 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Erythrocin Stearate HUMAN PRESCRIPTION DRUG LABEL 1 24338-106 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 24338-120 CAPSULE, DELAYED RELEASE 250 mg ORAL ANDA 27 sections